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Edited by Hans-Dieter KlenkAbstract The SARS-CoV open reading frame 6 (ORF6) is
transcribed into mRNA6 and encodes a putative 7.5 kDa acces-
sory protein, SARS 6, with unknown function. In this study, we
have conﬁrmed the SARS 6 protein expression in lung and intes-
tine tissues of the SARS patients and in SARS-CoV infected
Vero E6 cells by immunohistochemistry. Further studies by
immunoblot and confocal microscopy analyses revealed the
expression and the endoplasmic reticulum (ER) localization of
the recombinant SARS 6 protein in mammalian cells. Expression
of SARS 6 protein in mammalian cells elicits biological activity
of stimulating cellular DNA synthesis.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The severe acute respiratory syndrome (SARS) is an infec-
tious disease with mortality rate approximately 10% of the
cases and had spread over 30 countries in 2003 [1]. The path-
ogenic mechanisms of the causative agent, SARS-CoV, are not
well characterized.
The SARS-CoV genome analyses predicted fourteen ORFs.
ORFs 1a and 1b constitute the replicase genes required for vir-
al RNA synthesis. The remaining 12 ORFs encode the four
structural proteins, Spike (S), Membrane (M), Nucleocapsid
(N) and Envelope (E), as well as eight putative accessory pro-
teins varying in size and position in the genome [2,3]. The eight
putative accessory proteins share no homology to known pro-
teins.
The uniqueness of the SARS putative accessory proteins to
other known coronavirus might be crucial to the clinical man-
ifestation of SARS. However, the functions of SARS-CoV
hypothetical proteins are poorly understood. Recently, acces-*Corresponding author. Fax: +852 2603 7732.
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addition, the hypothetical protein 7a was shown to interact
with SARS 3a and the structural proteins in Vero E6 cells
[5,6]. These ﬁndings highlighted the potential functions of
these hypothetical proteins in the pathogenesis of SARS.
The SARS 6 protein is 63 amino acids in length, also known
as the X3 protein. A minimal transcription regulatory se-
quence is located upstream of the gene (ORF6) and its mRNA
(mRNA6) exists in SARS-CoV infected Vero cells [7,8]. In this
study, the expression and possible function of the SARS 6 pro-
tein were investigated.2. Materials and methods
2.1. Cell culture
Vero E6 (African green monkey kidney ﬁbroblasts) and CHO (Chi-
nese hamster ovary) cells were obtained from American Type Culture
Collection (Manassas, VA, USA). Cells were maintained in high glu-
cose DMEM (Gibco BRL Life Technologies Inc., Carlsbad, CA,
USA) containing 3.7 g/l sodium bicarbonate, 10% FBS, 100 U/ml pen-
icillin and 100 lg/ml streptomycin at 37 C in 5% CO2.
2.2. Selection of clinical specimens
Samples were selected retrospectively following the guidelines of lo-
cal ethical committee [9]. SARS was diagnosed according to previously
established criteria of the World Health Organization (www.who.int/
csr/sars/en/). The outbreak in the Prince of Wales Hospital, Hong
Kong, and the sequences of events leading to the world endemics
has been reported [10,11]. Pathology of all 8 autopsies has been previ-
ously described [12]. The control autopsies were chosen randomly at
around the same period of time (March–November) in preceding
years. The diagnosis included lung and non-lung pathology. These
controls were not age-matched and they had no SARS-CoV infection
as conﬁrmed by in situ hybridization and ﬁve diﬀerent antibodies to
SARS-CoV N, S, M and 3a proteins. For cases with pulmonary infec-
tion, routine cultures for common virus and bacteria had been per-
formed. Coronaviral infections of any kind were not suspected
clinically in these cases.
2.3. SARS-CoV infection of Vero E6 cells
The CUHK-W1 strain of SARS-CoV (GenBank Accession No.
AY278554) was grown and assayed in the cells [13,14]. Brieﬂy,
SARS-CoV was used to infect Vero E6 cells maintained in DMEM
with 10% FBS at 60–70% conﬂuence, and with a multiplicity of infec-
tion (MOI) of 10. Subsequently, cells were harvested at the desired
cytopathic eﬀect (CPE) for immunohistochemistry detection [9].blished by Elsevier B.V. All rights reserved.
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Rabbit anti-SARS 6 antibody (designated PUP3) was produced by
Abgent Inc. (San Diego, CA, USA) and Century Biotech Limited
(Hong Kong, China). The peptide sequence for antibody production
was TKKNYSELDDEEPMELDYP [9].
2.5. Immunohistochemical studies
Paraﬃn blocks were prepared from infected or control Vero cells
ﬁxed with 10% formalin. Autopsy specimens were ﬁxed with 10% for-
malin and embedded in paraﬃn blocks and standard avidin-biotin
method was used for immunohistochemical studies on 4-lm sections.
PUP3 antibodies (1:100 dilution) and StreptABComplex/HRP Duet
Reagent Set (DAKO, Glostrup, Danmark) were used with 3,3 0-diam-
inobenzidine tetrahydro-chloride as the chromogen. Antigen retrieval
was performed by microwave pretreatment twice in 10 mM citrate buf-
fer, pH 6.0, or 0.1 M EDTA buﬀer, pH 8.0, with preliminary heating at
780 W for 3 min followed by 480 W for 10 min.
2.6. Construction of SARS 6 protein expression vectors
The SARS 6 cDNA (CUHK-Su10, GenBank Accession No.
AY282752) [3] was subcloned into pEGFP-N1 (BD Bioscience, Clon-
tech, Palo Alto, CA, USA) and pcDNA3.1 (Invitrogen, Life Technol-
ogies, Carlsbad, CA, USA) vectors. For cloning the SARS 6–EGFP
(Enhanced green ﬂuorescent protein) fusion protein, the SARS 6
cDNA was PCR ampliﬁed using primer set SARS 6-GFP-F (5 0-
GGCGCCGAGCTCATGTTTCATCTTGTTGAC-30) and SARS 6-
GFP-R (5 0-CCGGGGTACCTCTGGATAATCTAACTCCAT-3 0),
incorporating SacI and KpnI sites for ligation into the pEGFP-N1 vec-
tor. To generate the untagged protein, the SARS 6 cDNA was PCR
ampliﬁed using forward primer SARS 6-F (5 0-GGCGCCGGTACC-
ATGTTTCATCTTGTTGAC-3 0) and reverse primer containing theFig. 1. Immunohistochemical staining of SARS 6 protein using anti-SARS
SARS patient. Terminal ileum sections of (C) SARS patient and (D) Non-Stranslation stop codon, SARS 6-R (5 0-GGCGCCTCTAGATTATG-
GATAATCTAACTC-30) incorporating KpnI and XbaI sites for liga-
tion into the pcDNA3.1 vector. These constructs were sequenced to
conﬁrm the correct identity and the orientation of the subcloned frag-
ments.
2.7. Expression of SARS 6 protein in Vero E6 and CHO cells
Plasmids were introduced into cells by Lipofectamine 2000 reagent
(Invitrogen, Life Technologies). To establish the polyclonal cell lines
with stable recombinant protein expression, cells harboring pEGFP-
N1-based constructs were exposed to 1000 lg/ml G418 (Sigma, St.
Louis, MO, USA) whereas cells harboring pcDNA3.1-based con-
structs were exposed to 120–200 lg/ml hygromycin B (Merck & Co.
Inc., NJ, USA) for a one-month selection period.
2.8. Immunoblot assay
Cells were suspended in PBS and lysed by sonication on ice. Cell
proteins were separated by SDS–PAGE and transferred onto a Hy-
bond membrane. The membrane was blocked with 5% non-fat dry
milk for 1 h and then incubated with primary antibody for 1.5 h at
room temperature. The membrane was then washed and incubated
with an appropriate secondary antibody for 1 h at room temperature.
The detection steps were performed using the enhanced chemilumines-
cent ECL kit (Amersham Biosciences, Buckinghamshire, UK).
2.9. Subcellular localization of SARS 6 protein
Cells were seeded on sterile coverslips in 12-well plates then transfec-
ted with SARS 6–EGFP fusion constructs and/or pDsRed2-ER mar-
ker plasmids (BD Bioscience, Clontech). 30 h posttransfection, cells
were washed and observed under a laser scanning confocal microscope
(Leica Model TCS-NT, Leica Microsystems, Heidelberg, Germany).6 antibody (PUP3). Lung sections of (A) SARS patient and (B) Non-
ARS patient. The arrowheads indicate the positive signals.
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Cells were plated in 24-well plates (0.7 · 105 cells/well) and syn-
chronized for 48 h in DMEM containing 0.1% FBS. DNA synthesis
was then perform by incubating cells in medium containing 10% FBS
and 1 lCi/ml [3H]-thymidine (Amersham Biosciences) for 24 h at
37 C. At the end of incubation, media were removed and cells were
washed with ice-cold PBS. Cellular macromolecules were then ﬁxed
with ice-cold 10% trichloroacetic acid (TCA). Unincorporated [3H]-
thymidine was removed by further washing steps. TCA precipitates
were dissolved by 1% SDS and subjected to scintillation counting
[15].3. Results and discussion
3.1. Detection of SARS 6 protein in SARS-CoV infected
patients and cells
By immunohistochemical staining, SARS 6 protein was de-
tected in pneumocytes of the lungs and surface enterocytes
of terminal ileum from eight SARS autopsy cases (representa-
tive data shown in Fig. 1A and C). Immunohistochemical sig-
nals were positive only in those tissues in which virus could be
isolated [9]. No positive signals were detected in the corre-
sponding tissues from ten non-SARS cases (Fig. 1B and D).
It is known that lung and small intestine are the primary tar-
gets of SARS-CoV infection [10]. Our results conﬁrmed that
the hypothetical SARS 6 protein indeed existed and expressed
in lung and intestine tissues of SARS-CoV infected clinical pa-
tients.Fig. 3. Expression of recombinant SARS 6 protein. (A) SARS 6–EGFP fus
anti-GFP antibody (1:3000 dilution). Lane 1–50 lg protein from pEGFP-N1
EGFP fusion protein-expressing Vero E6 cells. Lane 3–20 lg protein from
SARS 6–EGFP fusion protein-expressing CHO cells. (B) SARS 6–EGFP fusi
(PUP3) (1:3000 dilution). Lane 1–50 lg protein from SARS 6–EGFP fusion
3b–EGFP fusion protein-expressing cells. Lane 3–50 lg protein from pEGFP
Vero E6 cells probed with anti-SARS 6 antibody (PUP3) (1:3000). Lane 1–5
50 lg protein from pcDNA3.1 vector transfected cells.
Fig. 2. Immunohistochemical staining of SARS 6 protein in Vero E6 cells u
non-infected cells. The arrowheads indicate the positive signals.To further conﬁrm the expression of SARS 6 protein in
SARS-CoV infected cells, Vero E6 cells were infected with
SARS-CoV CUHK-W1 strain (GenBank Accession No.
AY278554) followed by immunohistochemical staining. The
results showed that SARS 6 protein was detected in SARS-
CoV infected cells but not in non-infected control cells.
Fig. 2A and 2B provides photographic details consistent with
previously described observations [9].
3.2. Expression of recombinant SARS 6 protein
The expression of the SARS 6–EGFP fusion protein was
determined by immunoblot assays using anti-GFP or anti-
SARS 6 (PUP3) primary antibodies (Fig. 3A and B). The
molecular weight of EGFP and SARS 6 protein are 27
and 7.5 kDa, respectively. In both Vero E6 and CHO cells,
the anti-GFP antibody recognized the expressed SARS 6–
EGFP fusion protein showing the anticipated 34.5 kDa
band (Fig. 3A, lanes 2 and 4). The PUP3 antibody also rec-
ognized a single band with the expected molecular size
(Fig. 3B). No signals were detected in Vero cells transfected
with SARS 3b–EGFP fusion constructs or pEGFP-N1 con-
trol vectors (Fig. 3B, lanes 2 and 3), indicating the speciﬁcity
of the antibody against the SARS 6 protein. Using the same
antibody, expression of the untagged SARS 6 protein in
Vero E6 cells was also conﬁrmed (Fig. 3C). Interestingly, gi-
ven the same amount of sample loading, the expression of
the untagged SARS 6 protein was weaker relative to theion protein-expressing Vero E6 cells and CHO cells were probed with
vector transfected Vero E6 cells. Lane 2–50 lg protein from SARS 6–
pEGFP-N1 vector transfected CHO cells. Lane 4–20 lg protein from
on protein-expressing Vero E6 cells probed with anti-SARS 6 antibody
protein-expressing cells. Lane 2–50 lg protein from SARS-CoV SARS
-N1 vector transfected cells. (C) Untagged SARS 6 protein-expressing
0 lg protein from untagged SARS 6 protein-expressing cells. Lane 2–
sing anti-SARS 6 antibody (PUP3): (A) SARS-CoV infected cells; (B)
6766 H. Geng et al. / FEBS Letters 579 (2005) 6763–6768expression of the SARS 6–EGFP fusion protein. The CMV
promoter drives protein expression in both pcDNA3.1 and
pEGFP-N1 vectors, the possibility that the SARS 6–EGFP
fusion protein has higher stability as compared to the un-Fig. 4. Subcellular localization of recombinant SARS 6 protein by confocal
fusion constructs and pDsRed2-ER marker plasmids showing (A) perinuclea
and (C) Merged image of colocalization of SARS 6 with the ER marker p
Subcellular localization of SARS 6–EGFP fusion protein expressed in CHOtagged SARS 6 protein cannot be excluded. The diﬀerence
in expression may also be due to the diﬀerences in the tem-
poral expression or transcription kinetics of the two plas-
mids.microscopy. (A)–(C) Vero E6 cells co-transfected with SARS 6–EGFP
r localization of SARS 6–EGFP fusion protein, (B) ER compartment,
rotein. (D) Subcellular localization of EGFP in Vero E6 cells. (E, F)
cells. (G, H) Subcellular localization of EGFP expressed in CHO cells.
Fig. 5. SARS-CoV SARS 6 expression stimulates DNA synthesis. 3H-
thymidine incorporation assays were performed on vector control and
SARS 6-expressing cells. (A) Stable CHO cell lines. Inset, transiently
transfected CHO cells (B). Stable Vero E6 cell lines. Inset (bar chart),
transiently transfected Vero E6 cells. Inset (gel photo): Immunoblot
conﬁrmation of stable expression of the SARS 6 protein in Vero E6
cells using the anti-SARS 6 antibody (PUP3). Each lane contained
50 lg total cell protein. Lane 1 – pcDNA3.1 vector transfected Vero E6
cells (vector control). Lane 2 – SARS 6-expressing Vero E6 cells. Each
bar represents the means ± S.D. of three to six experiments in triplicate
or quadruplicate set up and the diﬀerence between control and SARS
6-expressing cells was determined by Students t test with a signiﬁcance
determined at p < 0.05 level.
Table 1
Expression of SARS 6 stimulates DNA synthesis in several stable cell
lines derived from independent transfection
Cell line 3H-thymidine incorporation
Vector control cells
(means ± S.D. in DPM)
SARS 6-expressing cells
(means ± S.D. in DPM)
CHO 1 6107 ± 1601.5 8428 ± 1000.7*
CHO 2a 5741 ± 963.3 10451 ± 3194.2*
CHO 3 6431.5 ± 1312.7 10126 ± 2437.5*
Vero E6a 126622 ± 3775.3 137486 ± 6266.7*
aData presented in Fig. 5.
*Signiﬁcant diﬀerence between SARS 6-expressing and vector control
cell lines detected by Students t test (p < 0.05).
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The SARS 6 protein is expressed both in lung and intestine
of SARS patients and SARS-CoV infected Vero E6 cells by
immunohistochemical staining as shown in Figs. 1 and 2.
Although the speciﬁc subcellular localization of SARS 6 pro-
tein cannot be determined in these immunohistochemical re-
sults, notice the positive signals detected outside the nuclei of
the SARS-CoV infected Vero E6 cells (Fig. 2). The subcellular
localization of the SARS 6 protein in mammalian cells was fur-
ther determined by expressing the SARS 6–EGFP fusion con-
structs in Vero E6 and CHO cells. Confocal microscopy
showed that SARS 6–EGFP protein was localized to the per-
inuclear region and colocalized with ER marker (Fig. 4A–C)
in Vero E6 cells. A similar localization pattern of the SARS
6–EGFP was obtained in CHO cells (Fig. 4E and F). In con-
trast, the control EGFP protein was distributed throughout
the cells (Fig. 4D, G and H) as expected [16]. EGFP fusion
protein has been a commonly used marker to determine sub-
cellular localization of proteins, i.e., the HIV accessory protein
Vpr, to circumvent the need for immunoﬂuorescence staining
[16]. This approach is particularly suitable for the studies to
which the antibody supply is limited (i.e., the current study).
In many cases, the construction of a C-terminal fusion protein
retains the normal biological activity of the heterologous part-
ner [16–18]. Pewe et al., reported similar perinuclear subcellu-
lar localization of SARS 6 protein with HA tag on the
background of the neurotropic strains of mouse hepatitis virus
(MHV) in rodent cells [19]. The identiﬁcation of the SARS 6
protein subcellular localization laid the ground for further
understanding of its role in SARS-CoV biology. Nevertheless,
whether endoplasmic reticulum localized SARS 6 protein elic-
its any biological activities by interacting with other viral or
cellular proteins requires further investigation.
3.4. Thymidine incorporation studies
In the attempt to elucidate the biological function of the
SARS 6 protein, [3H]-thymidine incorporation was measured
in both CHO and Vero E6 cells expressing the untagged SARS
6 protein to evaluate its eﬀects on DNA synthesis. In these
experiments, since unincorporated [3H]-thymidine was re-
moved following the ﬁxation of macromolecules by TCA in
the washing steps, the cell associated radioactive counts in
these experiments reﬂect the actual DNA synthesis. Fig. 5
and Table 1 show that both transient and stable expression
of the SARS 6 protein induced DNA synthesis in CHO cells
(Fig. 5A) and in Vero E6 cells (Fig. 5B).
Viral accessory proteins have been shown to elicit function
in cell growth and survival. The HIV accessory protein Vpr
is not essential for HIV replication. However, Vpr induces cell
cycle arrest and apoptosis when expressed in cultured mamma-
lian cells [20,21]. In addition, human T-lymphotropic virus
type 1 (HTLV-1) accessory protein p12I is localized to the
endoplasmic reticulum and it can increase intracellular calcium
and cell proliferation [22]. It is speculated that a protein local-
ized to ER may modify intracellular signaling pathways by
regulating Ca2+ homeostasis in the ER and thus aﬀect cellular
DNA synthesis. Similarly, SARS-CoV may also evolve various
mechanisms to optimize cellular conditions to its own beneﬁt.
At the current stage, the signiﬁcance of SARS 6-induced DNA
synthesis in SARS-CoV biology remains elusive, since such
observation is obtained independent of the context of the
whole viral genome. Nevertheless, such biological activityfurther substantiates the expression of the SARS 6 protein in
the cells and implies its interaction with cellular components.
In conclusion, the evidence provided here indicates that the
SARS-CoV ORF6 encodes a viral protein which is expressed
6768 H. Geng et al. / FEBS Letters 579 (2005) 6763–6768both in lung and intestine of SARS patients and SARS-CoV
infected Vero E6 cells. Recombinant expression of the SARS
6 protein revealed its ER localization and biological activity
of stimulating cellular DNA synthesis.
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